New multicenter study highlights utility of daxor's blood volume analysis in heart failure care

Research published in the prestigious journal of cardiac failure from three institutions oak ridge, tn, feb. 13, 2025 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, today announces a multicenter study published in the prestigious journal of cardiac failure reporting pivotal insights for effective heart failure treatment through the use of daxor's blood volume analysis (bva). the study demonstrates how bva outperforms standard hemodynamic measurements in assessing heart failure volume status, while highlighting its unique capability to detect anemia, a crucial factor for effective treatment.
DXR Ratings Summary
DXR Quant Ranking